



IDT Australia - Generics Sales Update

***Temozolomide outperforming early expectations
Outlook for sales growth
More launches in 2017***

12 April 2017, Melbourne: IDT Australia Limited (IDT) updates the market with respect to the first quarter sales of its internally developed generic product temozolomide as well as the status of the commercialisation of further products.

IDT received approval from the US FDA for the marketing of its generic capsule containing temozolomide in April 2016. Temozolomide is a cytotoxic drug used in the treatment of brain cancer.

Temozolomide was launched by Mayne Pharma in November 2016. One batch of each of 7 strengths was shipped as launch stock. This stock was expected to be sufficient to meet Mayne Pharma's early market penetration efforts until mid 2017. Since launch, tendering success has been better than anticipated and a further order was recently received by IDT from Mayne Pharma for the 180mg and 250mg dose strengths, with an aggregate value which is larger than the launch stock. This replenishment stock is now in manufacture and expected to be shipped in FY17. Due to the structure of the distribution arrangements, revenue recognition for the profit share portion of the sales will fall in the first half of FY18.

Mayne Pharma's higher than anticipated market share is encouraging and should provide a solid platform for future temozolomide sales growth and operational efficiencies created by higher throughput manufacture.

While this represents a significantly faster market uptake than anticipated, IDT still has sufficient production capacity to meet further growth in market share for temozolomide.

Other products in the process of approval or development that should attain marketable status this calendar year include Pindolol, Leucovorin and Doxazosin. Mexiletine, Carbidopa/Levodopa and Prazosin are also under development with the products to be readied for launch after the launch of the first group of products. IDT is now well placed to realize the value for these assets following the completion of facility and equipment upgrades.

ENDS

For personal use only

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT Australia Ltd is developing a portfolio of 25 generic drugs to manufacture and sell via US distribution partners. With IDT's 2016 temozolomide ANDA approval this signifies IDT's move to rapidly become a specialty generics business with near term revenue upside.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

For personal use only